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Availability of essential drugs for 
managing HIV-related pain and 
symptoms within 120 PEPFAR-
funded health facilities in East Africa: 
A cross-sectional survey with onsite 
verification
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Eve Namisango5, Scott Moreland6, Nancy Gikaara5,  
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Abstract
Background: World Health Organization’s essential drugs list can control the highly prevalent HIV-related pain and symptoms. 
Availability of essential medicines directly influences clinicians’ ability to effectively manage distressing manifestations of HIV.
Aim: To determine the availability of pain and symptom controlling drugs in East Africa within President’s Emergency Plan for AIDS 
Relief–funded HIV health care facilities.
Design: Directly observed quantitative health facilities’ pharmacy stock review. We measured availability, expiration and stock-outs 
of specified drugs required for routine HIV management, including the World Health Organization pain ladder.
Setting: A stratified random sample in 120 President’s Emergency Plan for AIDS Relief–funded HIV care facilities (referral and district 
hospitals, health posts/centres and home-based care providers) in Kenya and Uganda.
Results: Non-opioid analgesics (73%) and co-trimoxazole (64%) were the most commonly available drugs and morphine (7%) the 
least. Drug availability was higher in hospitals and lower in health centres, health posts and home-based care facilities. Facilities 
generally did not use minimum stock levels, and stock-outs were frequently reported. The most common drugs had each been out 
of stock in the past 6 months in 47% of facilities stocking them. When a minimum stock level was defined, probability of a stock-out 
in the previous 6 months was 32.6%, compared to 45.5% when there was no defined minimum stock level (χ2 = 5.07, p = 0.024).
Conclusion: The data demonstrate poor essential drug availability, particularly analgesia, limited by facility type. The lack of strong 
opioids, isoniazid and paediatric formulations is concerning. Inadequate drug availability prevents implementation of simple clinical 
pain and symptom control protocols, causing unnecessary distress. Research is needed to identify supply chain mechanisms that lead 
to these problems.
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Introduction
During 2011, there were an estimated 23.5 million individ-
uals in sub-Saharan Africa living with HIV infection and 
1.8 million with new infections and 1.2 million HIV-related 
deaths.1 There is an increasing body of evidence that people 
living with HIV infection endure significant burdensome 
symptoms, including pain,2–5 fatigue, weight change, cough 
and skin problems,6 and that symptoms may persist along-
side antiretroviral treatment (ART).7 Infections such as 
tuberculosis (TB), pneumonia and candidiasis are a major 
cause of morbidity. Although recent guidance has raised the 
cluster of differentiation 4 (CD4) count at which ART 
should be initiated,8 patients with advanced disease will 
experience greater morbidity due to immune reconstitution 
syndrome.9 Greater pain and symptom burden are associ-
ated with reduced ART adherence5,10 and with a greater 
probability of switching ART regimens in settings where 
this is a possibility.11 Suboptimal adherence limits immuno-
logical and virologic responses to ART and increases the 
risk of mortality.12 Therefore, symptom management with 
optimal prevention and treatment of infections are required 
for the maximum impact on quality of life, morbidity and 
mortality for patients with HIV.
The pharmacological prevention and management of 
pain and opportunistic infections requires an effective 
health care delivery infrastructure, clinical skills and patient 
access to care.13 It also requires supplies that allow clini-
cians to prescribe and pharmacies to dispense those drugs 
known to be most effective in the prevention and control of 
common problems. Although data have suggested that 
stock-outs are a barrier to implementation of clinical guid-
ance with respect to co-trimoxazole (CTX) and isoniazid,14 
the availability of these and other essential drugs and the 
implementation of minimum stock levels (i.e. the specified 
lowest amount of a named drug available to dispense in the 
pharmacy before a re-order should be made) in line with 
standards for pharmacy and medicine management have 
not been described.15 This is especially true for pain man-
agement. In order for pain to be effectively controlled, clin-
ical staff should be skilled and able to access three ‘steps’ of 
analgesia according to the World Health Organization 
(WHO) pain ladder: non-opioids (such as paracetamol for 
mild pain), moving up to weak opioids (such as codeine 
with adjuvants as appropriate) and then to strong opioids 
(such as morphine with adjuvants as required).16 
Furthermore, analgesics should be not only given ‘by the 
ladder’ but also ‘by the clock’ and ‘by the mouth’. Therefore, 
effective pain control requires oral formulations that can be 
regularly taken by the patient wherever they may be – 
including at home and in the community – potentially plac-
ing a legislative burden on smaller and community-based 
providers who must adhere to legislative regulation of opi-
oid storage and prescribing.17
The constrained economic resources of countries within 
Africa have been identified as obstacles to drug availabil-
ity.18 These issues relate directly to infrastructure chal-
lenges, such as the number of qualified pharmacists and the 
efficiency of drug procurement and distribution. Further 
evidence suggests that supply of analgesics is unreliable 
among HIV care providers in sub-Saharan Africa and that 
legislation is overly restrictive for the stock and prescribing 
of opioids with regard to storage, duration of permissible 
prescription and designation of health professionals with 
the legal mandate to prescribe.17,19 However, although drug 
availability is reliant on a number of policy, regulatory and 
supply system factors, no studies to date have surveyed the 
availability within sub-Saharan Africa at the pharmacy 
level of drugs required by HIV patients to prevent and man-
age common problems. In the absence of such data, it is 
unlikely that the goals of HIV-focused health investment in 
Africa can be fully realised or patient outcomes optimised.
In 2003, the US Government (USG) funded a 5-year, 
US$15 billion initiative to combat the global HIV/AIDS 
epidemic: the President’s Emergency Plan for AIDS Relief 
(PEPFAR). The funds were allocated approximately as fol-
lows: treatment (55%), prevention (20%), assisting orphans 
and vulnerable children (10%) and care and support of indi-
viduals with HIV/AIDS (15%). In 2008, PEPFAR was 
reauthorized for a further 5 years up to US$48 billion. 
Evaluation of the effect of PEPFAR funding in its target 
countries has established that there has been a decrease in 
HIV-related deaths20 and a reduction in the number of HIV-
positive births.21 While the focus on increased access to 
ART has achieved results, there has been little investigation 
from an operational and implementation perspective.22,23 
Lack of attention to the dimensions that directly assess the 
ability to implement simple protocols for effective care, 
and reduce unnecessary suffering, may undermine and 
diminish the gains brought by improved ART access. As 
part of a larger mixed-methods Public Health Evaluation of 
PEPFAR HIV care and support services in Kenya and 
Uganda,24 this investigation aimed to determine within 
health facilities the availability, minimum stock levels and 
stock-out frequencies of drugs commonly required for the 
prevention and management of problems in people with 
HIV infection.
Methods
Design
The study design was a cross-sectional quantitative phar-
macy review in a stratified random sample of HIV facility 
pharmacies in two sub-Saharan African countries.
Setting and sampling
The study was conducted among HIV care facilities in 
Kenya and Uganda. In each country, of around 600 HIV 
care facilities receiving PEPFAR funding, 60 were selected 
by stratified random sampling. In order to sample a range 
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of facility sizes within the study population, facilities were 
stratified by number of patients seen for HIV care, using 
locally provided partner activity data from the non-govern-
mental organisations (NGOs) implementing care and sup-
port at the facility level. The three strata (specified a priori) 
were 1–100, 101–500 and >500 patients seen per year. 
Inclusion criteria were that they received PEPFAR funding 
to provide HIV care and support, that they provided care to 
adults and that they operated in an area that was safe for 
researchers to visit at the time of data collection. This latter 
criterion was operationalised as unsafe sites were in areas 
where violent unrest was reported. Facilities which did not 
meet the inclusion criteria were replaced using the same 
random process.
Tool development
Tools were developed by a multidisciplinary team across 
the focus and academic lead countries (the United Kingdom, 
Kenya, Uganda and the United States). All tools were 
piloted in one large facility and in one small facility. 
Following piloting, the wording and structure of the tools 
were modified and clarified. At each participating site, 
information was collected on facility type, total number of 
registered patients and for each drug, the presence, amount 
currently in stock, whether drug had expired, number of 
unopened packs present, minimum stock level (in packs) 
and whether a stock-out had occurred in the previous 6 
months. A minimum stock level is the quantity of remain-
ing stock which prompts the facility to make another order. 
Drugs were organised by delivery method (i.e. tablet form, 
syrup, powder for suspension and injection).
The selection of drugs for this study focused on those 
that prevent and treat common and burdensome problems 
of people with HIV, are present on the most recent WHO 
essential drugs list25 and are in line with current prescribing 
practice, that is, analgesia according to the WHO pain lad-
der: CTX, isoniazid and fluconazole. CTX is a simple, 
well-tolerated and cost-effective intervention,26 which has 
been proven to reduce HIV morbidity and mortality in 
developing countries.27–30 WHO16 recommends CTX for all 
HIV-infected persons at WHO clinical stages 2, 3 or 4 or for 
persons with CD4 < 350 per mm3, as well as for all infants 
exposed to HIV as an integrated component of HIV chronic 
care.31
TB is the most common life-threatening opportunistic 
infection for those with HIV disease, and preventive iso-
niazid therapy can reduce the risk of TB by 33% overall 
and by 64% for those with a positive tuberculin skin test.32 
Joint United Nations Programme on HIV/AIDS (UNAIDS) 
and WHO have designated isoniazid as part of an essential 
HIV care package,33 even alongside ART as it also has 
been shown to reduce morbidity32 and has fewer side 
effects than its alternatives.34 The WHO recommends iso-
niazid preventive therapy for all HIV-positive individuals 
at high risk of TB.35
Oral or intravenous (IV) fluconazole is used in the treat-
ment of oropharyngeal, oesophageal and vulvovaginal can-
didiasis in HIV patients, and infected patients may benefit 
from long-term suppressive or maintenance therapy with 
fluconazole to prevent recurrence or relapse of infections 
such as coccidioidomycosis, cryptococcosis, histoplasmo-
sis, mucocutaneous candidiasis and cryptococcal meningi-
tis. It is also active in HIV-positive adults and children. 
Fluconazole is also being tested as a drug for treatment or 
prophylaxis for other fungal diseases such as aspergillosis, 
coccidioidomycosis and histoplasmosis36–39 and is recom-
mended as part of essential HIV care in Kenya.40
Due to the high prevalence of pain at all stages of the 
HIV trajectory and alongside treatment, the analgesics from 
the essential drugs list (i.e. non-opioid, weak opioid and 
strong opioid) ensure that the WHO pain ladder16 can be 
adhered to and pain effectively controlled. The pain ladder 
has been demonstrated to be highly effective in pain con-
trol, and good clinical practice requires drugs to be availa-
ble at all three levels of the ladder.
Data collection
All sampled facilities were approached for participation by 
the countries’ Ministry of Health (although some sites were 
NGOs and mission facilities, they were contacted by the 
Ministry through their country coordinating function). 
Project-specific local researchers attended the sampled 
facilities to complete the data collection tools. This was done 
without prior notice to the facilities so that the data could be 
collected from pharmacies without any potential facility 
effort to enhance the organisation, stock levels or supply of 
drugs. All pharmacy data were researcher-collected with the 
attending pharmacist, with facility information being 
obtained from staff on the day of the visit. Data were recorded 
on two identical recording sheets. One copy was left with the 
facility and the other returned to the local research office for 
data entry.
Data management and analysis
Data were transferred from sampled facilities to the local 
study offices immediately following collection. Data were 
double-entered by two different researchers and subse-
quently validated using EpiData v3.1 (EpiData Association, 
Odense, Denmark; 2000–2008). Errors in data entry and 
data recording were identified using consistency and logic 
checks and followed up by manual checking of question-
naires. Stata v10 (Stata Corp LP, College Station, TX, USA; 
2007) was used to undertake descriptive analysis and tests 
of association.
Ethical approval
Ethical approval to undertake the study was received from 
the Uganda National Council for Science and Technology 
296 Palliative Medicine 28(4)
(UNCST; Ref SS 1964), the Kenyan Medical Research 
Institute (Ref KEMRI/RES/7/3/1) and the College Research 
Ethics Committee at King’s College London (Ref 
CREC/06/07-140). Subsequent tool changes following ini-
tial piloting were also approved.
Results
Sample facility characteristics
Of the original selected facilities (60 Kenya, 60 Uganda), 11 
(3 facilities in Kenya and 8 facilities in Uganda) were found 
not to meet the inclusion criteria. Five sites could not be 
found, four were in an area of civil unrest, one was exclu-
sively paediatric and one was a duplicate. Therefore, a fur-
ther 11 equivalent facilities were selected from the original 
stratified random sample to make a sample size of 120 facil-
ities visited.
The types of health facilities visited, as described by 
senior staff, are presented in Table 1. Referral hospitals/
institutions are defined as those at national/regional or pro-
vincial level which provide surgery, specialised care and 
sometimes training. District hospitals offer basic inpatient 
services only and not necessarily surgery. Health centres 
offer predominantly outpatient care, lower level health cen-
tres (commonly ‘Health Posts’ in Kenya) offer only a lim-
ited range of outpatient-only services and home-based care 
(HBC) services offer little clinical care. These definitions 
were locally determined by the Ministry of Health–led 
Country Teams, and the categorisation was determined by 
the participating facilities.
One HBC facility in Uganda was found to have no 
drug dispensing facilities although it had met the inclu-
sion criteria for a care and support provider. As a result, 
it was removed from the analysis, leaving 59 facilities in 
Uganda.
The largest proportions of Kenyan sites were district 
hospitals and health centres, and the largest proportion of 
Ugandan sites was health centres. Uganda had a larger 
number of health centres which were generally smaller 
(with respect to patient numbers) than the average size for 
Kenya. Lower level health centres/health posts were also 
smaller in Uganda than Kenya. Table 1 shows the median 
number of patients in the previous year (as reported by 
facility staff) by facility type and country.
Although the sampling frame was stratified by number 
of patients according to routine reported data, the median 
number of patients per facility by facility type as reported 
by facility staff on the day of survey was found to be very 
different between countries (Table 1). Consequently, fur-
ther analysis was conducted by facility type rather than 
patient population number in each country.
Drug availability
Non-opioid analgesics (73%) and adult CTX (64%) were 
the most commonly available drugs, and morphine (7%) 
and isoniazid (23%) were the least commonly available 
drugs (Table 2). Fluconazole and paediatric CTX were each 
available in over half of facilities. Drug availability was 
generally higher in hospitals and lower in smaller facilities 
(health centres, health posts and HBC facilities). Only a 
few HBC facilities stocked drugs, which were non-opioid 
analgesics and CTX.
Drug stocks and formulations
The type and quantity of stock are represented in Table 3. 
Data were collected by formulation, but information on 
strength and dosage was not collected. Therefore, it is not 
possible to amalgamate the different formulations into an 
overall quantity and they are presented separately. The 
most commonly available formulation for every drug 
(except paediatric CTX) was tablets. Syrup formulation 
was rarely available for the drugs examined except for non-
opioid analgesics (49 facilities) and paediatric CTX (56 
facilities). As paediatric CTX is the only drug in the study 
specifically for children and the only drug most commonly 
available in syrup form, findings for this drug are reported 
separately.
Table 1. Facility type and number of registered HIV patients.
Facility type Kenya Uganda
 
Number of 
facilities
Median number of registered HIV 
patients reported by facilities (IQR)
Number of 
facilities
Median number of registered HIV 
patients reported by facilities (IQR)
Referral hospital/institution 9 1711 (1126–3031) 5 1383 (1038–2619)
District hospital 15 1259 (799–4713) 4 2646 (1684–10,061)
Health centre 15 2243 (374–5687) 27 335 (200–1262)
Health post 11 1162 (688–2096) 13 75 (50–144)
Home-based care 10 178 (45–480) 10 327 (200–371)
Total 60 1167 (374–3450) 59 314 (127–1383)
IQR: interquartile range.
Information on number of patients was not available for one health centre in Uganda and two district hospitals in Kenya.
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Overall, there was great variation between facilities in 
the amount of drugs in stock. The most commonly availa-
ble drugs were also those with the highest amount in stock 
on the day of the survey. The amount of in-date non-opioid 
analgesics (median: 5000 tablets and 8000 mL of syrup) 
and adult CTX (median: 5300 tablets and 18,050 mL of 
syrup) in stock on the day of the survey was far greater than 
all the other drugs examined. As the stock levels for all 
facilities were examined together, the amount of drugs 
available per 1000 registered patients was calculated. 
Again, the amount of drugs available per 1000 patients was 
far greater for non-opioid analgesics (8732 tablets and 
11,634 mL) and for adult CTX (24,314 tablets) than for the 
other drugs (ranging from 2 tablets per 1000 patients for 
morphine to 231 tablets per patient for fluconazole). Nearly 
half (56) of facilities stocked paediatric CTX in syrup form, 
with a large amount found in stock on the day of survey 
(median: 15,000 mL) and a high availability per child reg-
istered.
Minimum stock levels, stock-outs and 
expired drug stocks
Facilities generally did not have minimum stock levels for 
the drugs studied (Table 4). The proportion of facilities 
with a minimum stock level ranged from 11% of those 
stocking paediatric CTX syrup to a high of 50% of facilities 
stocking morphine (tablets or syrup) or adult CTX syrup. 
Minimum stock levels were used for at least one drug at 
21% of referral hospitals, 32% of district hospitals, 33% of 
health centres and 17% of health posts. None of the HBC 
facilities used minimum stock levels.
Stock-outs were frequently reported. The frequency var-
ied by type of drug. The most commonly stocked drugs 
(non-opioid tablets and adult CTX tablets) had each been 
out of stock in the past 6 months in 47% of facilities stock-
ing them. Morphine tablets and fluconazole syrup had been 
out of stock in the previous 6 months in all the facilities that 
stocked them (4 and 2 facilities, respectively), whereas 
morphine powder, injectable morphine, isoniazid syrup and 
paediatric CTX powder had not been out of stock in the last 
6 months at any of the facilities stocking them (found in 1, 
4, 1 and 1 facilities, respectively).
When a minimum stock level was defined, the probabil-
ity of a stock-out in the previous 6 months was 32.6%, 
compared to 45.5% when there was no defined minimum 
stock level. This difference in the probability of a stock-out 
was statistically significant (χ2 = 5.07, p = 0.024).
Discussion
This study measured the availability and stocks of seven 
commonly required drugs for the management of prevalent 
HIV-related conditions, such as pain and opportunistic 
infections in line with WHO essential drug lists and the 
WHO pain ladder, in PEPFAR-funded HIV care and treat-
ment facilities in Kenya and Uganda. The results demon-
strate that facility drug stocks for the management of pain 
and the prevention and treatment of infections in patients 
with HIV are inadequate in both range and quantity. This 
drastically compromises the ability of facility staff to man-
age symptoms and to adhere to basic care protocols.40 The 
results were particularly poor for the peripheral health 
facilities. Health posts are often the first health system con-
tact for many HIV patients, yet these findings suggest that 
the majority surveyed were unable to dispense the drugs for 
the most common symptoms and conditions.
With respect to pain control, it is concerning that even 
Step 1 (i.e. non-opioid) analgesics were not available in a 
large number of facilities and were commonly reported as 
having stock-outs. Step 3 analgesia (i.e. morphine) was 
only stocked in 8 of the 119 facilities, although the restric-
tive legislation would preclude many lower level health 
providers from stocking opioids. Furthermore, a substantial 
contribution to the availability of morphine was the injec-
tion form, and when examined more closely, stocks were 
found to consist of only between 10 and 12 vials. This for-
Table 2. Drug availability by facility type.
Drug, any 
formulation, in date
Facilities stocking drug, n (%)
 Referral hospital 
(n = 14)
District hospital 
(n = 19)
Health centre 
(n = 42)
Health post 
(n = 24)
HBC (n = 20) Total (n = 119)
Non-opioid analgesic 14 (100) 18 (95) 35 (83) 17 (71) 3 (15) 87 (73)
Codeine 10 (71) 13 (68) 14 (33) 3 (13) 0 40 (34)
Morphine 1(7) 2 (11) 5 (12) 0 0 8 (7)
Isoniazid 4 (29) 4 (21) 15 (36) 4 (17) 0 27 (23)
Fluconazole 13 (93) 17 (89) 27 (64) 2 (8) 0 59 (50)
Adult CTX 14 (100) 17 (89) 25 (60) 17 (71) 3 (15) 76 (64)
Paediatric CTX 11 (79) 15 (79) 27 (64) 10 (42) 1 (5) 64 (54)
HBC: home-based care; CTX: co-trimoxazole.
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mulation and quantity of morphine is not suitable for the 
management of severe pain in HIV. The WHO pain ladder 
stipulates analgesia by the mouth and by the clock;16 there-
fore, injectable opioids are not appropriate, particularly for 
patients in the community. Our findings on the availability 
of analgesia are concerning in the light of the evidence of 
pain prevalence, which in African home-care HIV patients 
has had a reported prevalence of 89% and has been found to 
be associated with great physical and psychological dis-
tress.41 Furthermore, 41% of outpatients in Tanzania with 
full ART access reported non-neuropathic pain which was 
not treatable with paracetamol (i.e. Step 1 analgesia),7 and 
the prevalence of pain in advanced AIDS is 98%.2 Stocks of 
codeine and morphine found in our study are insufficient to 
manage this prevalence and intensity of pain. Our finding 
that opioids were expired within pharmacies supports ear-
lier data from a single East African pharmacy and qualita-
tive data that propose under-treatment of severe pain due to 
‘opiophobia’ among clinicians.19
This study found that it was much more common for 
facilities to suffer stock-outs than to have expired drugs in 
the pharmacy. This suggests that facilities were more likely 
to have too few drugs supplied, rather than too many. The 
exception was morphine; there were only 11 instances of 
in-date morphine being found (some within the same facil-
ity), five stock-outs and three facilities with expired mor-
phine. Thus, it appears that not only was morphine rarely 
available but also the little that was present was not used. 
This finding supports previous studies.17,19
Although pharmacies rarely had minimum stock levels, 
facilities which used minimum stock levels to govern the 
quantity of stock held were less likely to report stock-outs 
than facilities which did not. Therefore, health system 
strengthening may be achieved by simple efforts to imple-
ment the established pharmacy and medicine management 
guidance on minimum stock levels,15 although our data also 
suggest that minimum stock levels alone will not prevent 
all stock-outs.
The study has several strengths and limitations. Data 
were collected by research staff visiting each facility with-
out prior notice, so the results were not based on staff 
reports and are likely to reflect the situation faced by phar-
macies and patients. As the study was supported by a funder 
of the facilities surveyed, we did not want to influence the 
organisation, stock level or supply of drugs by giving warn-
ing or the pharmacy review, thereby potentially biasing our 
data. All visited facilities consented to participate in the 
study, and data were collected on different formulations as 
well as different drugs. In order to simplify the study data 
collection and reporting, we did not collect data on the 
strength of each formulation, although this limits the depth 
to which the data can be analysed with regard to patient 
supply. It may be that available stocks were only in low 
dose formulations, and the lack of detailed data limits the 
possibility to further interrogate the data on availability by 
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patient population. In this study, we chose not to collect 
data on antiretroviral (ARV) supplies as there is an estab-
lished literature researching the accessibility and sustaina-
bility of ARV delivery.42,43 This study therefore focused on 
the essential WHO supportive care drugs and WHO pain 
ladder that are frequently required alongside ARVs to max-
imise quality of life for patients with HIV. It was beyond 
the scope of this study to explore drug supply chain issues 
that may explain some of the observed results. Further 
study is urgently required at the policy, regulatory and cen-
tral supply levels. Such data will give important context to 
interpret our data on the availability at pharmacy level and 
give greater ability to determine at which point in the sup-
ply chain problems are occurring. An example of where 
more research is needed is a greater understanding of why, 
in our study, stock-outs are experienced even in those facil-
ities that apply minimum stock levels. Prescribing practice 
is also an important factor in understanding appropriate 
stock levels. If decentralisation of treatment and care is to 
be pursued at the policy level,44 then greater focus is needed 
to understand the challenges to drug availability at rural 
and community levels.
When ART and routine monitoring are free of charge to 
the patient, as they were in the surveyed facilities, HIV 
care still quadruples family health care expenditure.45 The 
major costs to patients are diagnosis and treatment of mor-
bidity events and transportation to health services. When 
drugs are unavailable, patients are more likely to need to 
visit other health facilities or pharmacies, thus increasing 
transport costs. The extra effort involved is also an unman-
ageable burden, given the high prevalence of fatigue in 
HIV.46 It is therefore unacceptable to require patients to 
‘shop around’ to maintain a steady supply of essential 
drugs. Further study to understand the medicine-seeking 
behaviour of patients would enhance the ability to provide 
reliable and adequate supplies of drugs in appropriate 
facilities and access points. Finally, the political economy 
of drug availability requires attention in light of these data. 
As noted in the ‘Background’ section, the allocation of 
ring-fenced funds to ART under PEPFAR has been associ-
ated with reduced HIV mortality and improved mother to 
child transmission. Despite the varying complexities of 
ART procurement, storage, prescribing, patient monitoring 
and adherence, there have been great successes in roll-out 
of these complex and expensive drugs47 (although sys-
temic and operational challenges persist).48 The cheaper 
and simpler pain and symptom preventing and controlling 
drugs, which are also seen as essential in the presence of 
ART and have clearly demonstrated benefits for mortality 
and morbidity, may benefit from equal effort to enhance 
supply and access.
This study demonstrates that there is a great need to 
improve health facility pharmacy stocks and the availability 
of essential drug formulations for the management of HIV-
related symptoms and to minimise costs and inconvenience 
to patients. Not only do funders and governments need to 
Table 4. Stock levels, recorded stock-outs and expired drugs found in pharmacies.
Drug type Formulation Number of facilities where stock 
level reported (percentage of 
those where drug stocked)
Number of facilities stocking the 
drug to have recorded stock-out 
in last 6 months (%)
Number of facilities with 
expired drug in stock
Non-opioid Tablets 19 (22) 40 (47) 1
 Syrup 6 (12) 24 (49) 0
 Powder 0 0 1
Codeine Tablets 8 (21) 13 (33) 0
 Syrup 0 1 (50) 1
 Powder 0 0 1
Morphine Tablets 2 (50) 4 (100) 1
 Syrup 1 (50) 1 (50) 1
 Powder 0 0 0
 Injection 2 (50) 0 1
Isoniazid Tablets 5 (19) 9 (33) 2
 Syrup 0 0 0
Fluconazole Tablets 13 (22) 26 (45) 1
 Syrup 0 2 (100) 2
 Powder 1 (14) 4 (57) 3
Adult CTX Tablets 24 (28) 40 (47) 1
 Syrup 2 (50) 1 (25) 0
Paediatric CTX Tablets 6 (43) 5 (36) 0
 Syrup 6 (11) 23 (41) 0
 Powder 0 0 0
CTX: co-trimoxazole.
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ensure that the facility pharmacy supply chain is secure but 
also the use of minimum stock levels and local management 
of supplies need to be promoted at the facility level. Attention 
to these simple procedures would greatly enhance the control 
of unnecessary pain and symptom burden.
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